Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 13,466 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2608204, Glimepiride; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 18
States / cities: Anaheim, California • Lancaster, California • Spring Valley, California + 15 more

Conditions: Gastric Cancer, Pancreatic Cancer
Interventions: CT041; Biological
Lead sponsor: CARsgen Therapeutics Co., Ltd.; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2035
U.S. locations: 15
States / cities: Duarte, California • Los Angeles, California • San Diego, California + 11 more

Conditions: Diabetes, Obesity
Interventions: Neomycin, Rifaximin; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypothyroidism
Interventions: Calcitonin; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 88 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Polycystic Ovary Syndrome, Infertility
Interventions: Clomiphene, Letrozole; Drug
Lead sponsor: Rachel Mejia; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Metabolic Syndrome X, Prediabetic State, Insulin Resistance, Obesity, Metabolic Diseases
Interventions: Dietary supplement for weight loss, Education and counseling for weight loss; Drug · Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pre-diabetes, Overweight, Metabolic Syndrome
Interventions: Diabetes Genetic Counseling, No genetic counseling; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Short Stature
Interventions: Growth Hormone; Drug
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 5 Years to 11 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: Healthium; Behavioral
Lead sponsor: Bastyr University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Insulin Resistance, Hyperglycemia
Interventions: insulin-like growth factor I; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 14 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Pancreatitis, Pancreatic Cancer
Interventions: triamcinolone, 98% dehydrated alcohol; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Type 1 Diabetes
Interventions: VC-01 Combination Product; Combination Product
Lead sponsor: ViaCyte; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Escondido, California • Walnut Creek, California • Atlanta, Georgia + 1 more

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: docetaxel; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 66
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 53 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, BI 1356 dose 3 once daily, BI 1356 dose 2 once daily, BI 1356 dose 1 once daily, Metformin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 34
States / cities: Chula Vista, California • La Jolla, California • Walnut Creek, California + 30 more

Conditions: Type 2 Diabetes, Diabetes
Interventions: Diabetes Self Management Program; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Diabetes Mellitus, Type 2, Dyslipidemia Associated With Type II Diabetes Mellitus, Percutaneous Coronary Intervention
Interventions: Evolocumab, Placebo; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: Not listed
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Pregnancy Weight Gain, Postpartum Weight Retention, Childhood Obesity, Gestational Diabetes, Overweight and Obesity
Interventions: Healthy for Two/Healthy for You; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Blood Pressure, Diabetes, Obesity, Insulin Resistance, Diuretics Drug Reactions, Sympathetic Nerve Activity
Interventions: Hydrochlorothiazide 12.5Mg Tab, Clonidine Pill, Placebo; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 79 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Diabetes Mellitus
Interventions: FreeStyle Libre Flash Glucose Monitoring System; Device
Lead sponsor: Abbott Diabetes Care; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Santa Barbara, California • Aurora, Colorado • Idaho Falls, Idaho + 1 more

Conditions: Healthy Adult, Type 1 Diabetes (T1D)
Interventions: phone call, email/mail; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 1 Year to 99 Years
Enrollment: 3,800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Type 2 Diabetes Mellitus, Insulin Resistance
Interventions: Metformin, saxagliptin, AZD9668, placebo; Drug
Lead sponsor: Nick Giannoukakis, PhD; Other
Eligibility: 21 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
Interventions: LY2382770, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 25 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 28
States / cities: Phoenix, Arizona • Inglewood, California • Los Angeles, California + 25 more

Conditions: Diabetic Neuropathy, Painful
Interventions: AGN 203818, placebo capsule; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Vitamin d Deficiency, Secondary Hyperparathyroidism
Interventions: CTAP101, Placebo; Drug
Lead sponsor: OPKO Health, Inc.; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Columbus, Ohio • Greenville, South Carolina

Search by objective public record fields.

A Study in Patients With Type 2 Diabetes

Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

Role of Methane in Glycemic Control

Hypothyroidism Treated With Calcitonin

Combined Letrozole and Clomid in Women With Infertility and PCOS

Education, Counseling, and Drug Therapy to Reduce Symptoms of Metabolic Syndrome

Genetic Counseling and Lifestyle Change for Diabetes Prevention

The Role of Igf-1 Generation Test in Diagnosis and Treatment of Short Stature

In-Home Weight Loss Program for Adults With Type 2 Diabetes Delivered by Interactive Cable Television Technology

Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance

A Prospective Study of EUS Guided Celiac Block

A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus

Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

Improving Self Management Skills of Older Adults With Diabetes

Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus

Pragmatic Randomized Clinical Trial to Limit Weight Gain in Pregnancy and Prevent Obesity

Mitigating the Pro-inflammatory Phenotype of Obesity

FreeStyle Libre Flash Glucose Monitoring System Post Approval Study for Pediatric Patients

Finding Immune Nascent Type 1 Diabetes

Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

A Study in Participants With Diabetic Kidney Disease

Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy

Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism